Ahmed Hilmy

Ahmed Hilmy is an experienced synthetic chemist specializing in drug discovery and development for mental and neurological diseases at Cybin Inc. since June 2021, where assistance is provided to CROs and CMOS with synthesis challenges. Prior roles include a scientist at Amgen, focusing on synthesizing and characterizing impurities, and a synthetic organic/medicinal chemist at Mersana Therapeutics, where novel linkers and toxins for antibody-drug conjugates were developed. Additional expertise was gained at Boston University/Whitehead Institute in process optimization for drug discovery in oncology, and at Genzyme/Sanofi as a staff scientist collaborating on medicinal chemistry projects. Ahmed Hilmy's career began as a principal associate chemist at Pharm-Eco, Inc./Johnson Matthey Pharma Services, performing process development for complex syntheses. Educational background includes an MBA and MS in organic chemistry from UMass Boston, complemented by a Bachelor of Science in chemistry and physics.